Molecular regulation of thyroid gland function

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 5, 2010, Pages 396-401

  Eggo, Margaret C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

mitogen activated protein kinase; PI3K; plasminogen; thyroid; vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR; POLYPHOSPHOINOSITIDE; RAP PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; THYROID HORMONE; VASCULOTROPIN;

ANGIOGENESIS; CANCER CELL; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN METABOLISM; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; THROMBOSIS; THYROID CANCER; THYROID GLAND;

ACETYLCYSTEINE; ANIMALS; ERYTHROMYCIN; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTEGRINS; IODIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE HYDROLASES; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMINOGEN ACTIVATORS; RATS; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956265815     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833c8942     Document Type: Review

References (70)

1. Bidey SP, Hill DJ, Eggo MC. Growth factors and goitrogenesis. J Endocrinol 1999; 160:321-332.
2. Ragno P, Montuori N, Covelli B, et al. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res 1998; 58:1315-1319.
3. Montuori N, Salzano S, Rossi G, Ragno P. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor. FEBS Lett 2000; 476:166-170.
4. Susarla R, Watkinson JC, Eggo MC. Regulation of plasminogen activators in human thyroid follicular cells and their relationship to differentiated function. J Cell Physiol 2007; 212:643-654.
5. Davis PJ, Davis FB, Lin H, et al. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab 2009; 297:E1238-E1246.
6. Wipff P, Hinz B. Integrins and the activation of latent transforming growth factor beta1: an intimate relationship. Eur J cell Biol 2008; 87:601-615.
7. Illario M, Cavallo AL, Monaco S, et al. Fibronectin-induced proliferation in thyroid cells is mediated by alphavbeta3 integrin through Ras/Raf-1/MEK/ERK and calcium/CaMKII signals. J Clin Endocrinol Metab 2005; 90:2865-2873.
8. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009; 14:4575-4587.
9. Giraud A, Dicristofaro J, DeMicco C, et al.A plasminogen-like protein, present in the apical extracellular environment of thyroid epithelial cells, degrades thyroglobulin in vitro. Biochem Biophys Res Commun 2005; 338:1000-1004.
10. Giraud A, Chabaud O, Lejeune P, et al. The plasminogen-like molecule apically secreted by epithelial thyroid cells is sulfated. Biochem Biophys Res Commun 2006; 346:746-750.
11. Giraud A, Lejeune P, Barbaria J, Mallet B. A plasminogen-like protease in thyroid rough microsomes degrades thyroperoxidase and thyroglobulin. Endocrinology 2007; 148:2886-2893.
12. Herbert JM, Lamarche I, Carmeliet P. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J Biol Chem 1997; 272:23585-23591.
13. Carmeliet P, Moons L, Lijnen R, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17:439-444.
14. Buergy D, Weber T, Maurer GD, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 2009; 125:894-901.
15. Tian X, Cong M, Zhou W, et al. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res 2008; 36:699-703.
16. Tan H, Ye K, Wang Z, Tang H. Clinicopathologic evaluation of immunohis-tochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma. Jpn J Clin Oncol 2008; 38:528-533.
17. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4:1317-1326.
18. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97:336-342.
19. Ahmad A, Kong D, Sarkar SH, et al. Inactivation of uPA and its receptor uPAR bull; by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 2009; 107:516-527.
20. Ahmad A, Kong D, Wang Z, et al. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009; 108:916-925.
21. Emami N, Diamandis EP. Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGF beta 1 in semen. Biol Chem 2010; 391:85-95.
22. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system. J Biol Chem 1994; 269:26775-26782.
23. Fanelli A, Grollman EF, Wang D, Philp NJ. MCT1 and its accessory protein CD147 are differentially regulated by TSH in rat thyroid cells. Am J Physiol Endocrinol Metab 2003; 285:E1223-E1229.
24. Tan H, Ye K, Wang Z, Tang H. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma. Transl Res 2008; 152:143-149.
25. Aratake Y, Marutsuka K, Kiyoyama K, et al. EMMPRIN (CD147) expression bull; and differentiation of papillary thyroid carcinoma: implications for immunocy-tochemistry in FNA cytology. Cytopathology 2010; 21:103-110.
26. Winkler E, Hobson S, Fukumori A, et al. Purification, pharmacological mod-ulation, and biochemical characterization of interactors of endogenous human gamma-secretase. Biochemistry 2009; 48:1183-1197.
27. Kim S, Kang HY, Nam E, et al. TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis 2010; 31:597-606.
28. Hu K, Yang J, Tanaka S, et al. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281:2120-2127.
29. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11:23-36.
30. Prager GW, Mihaly J, Brunner PM, et al. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood 2009; 113:1383-1390.
31. Riesco-Eizaguirre G, Rodŕ?guez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009; 69:8317-8325.
32. Schweppe RE, Kerege AA, Sharma V, et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid 2009; 19:825-835.
33. Miller KA, Yeager N, Baker K, et al. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009; 69:3689-3694.
34. Kim CS, Zhu X. Lessons from mouse models of thyroid cancer. Thyroid 2009; 19:1317-1331.
35. Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma ells. J Clin Endocrinol Metab 2010; 95:450-455.
36. Gin N, Jiang T, Rosen DM, et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009; 94:4107-4112.
37. Eggo MC, Bachrach LK, Burrow GN. Interaction of TSH, insulin and insulinlike growth factors in regulating thyroid growth and function. Growth Factors 1990; 2:99-109.
38. Grozovsky R, Morales MM, Carvalho DP. Biphasic modulation of insulin receptor substrate-1 during goitrogenesis. Braz J Med Biol Res 2007; 40:679-686.
39. Lee S, Lynn EG, Kim J, Quon MJ. Protein kinase C-zeta phosphorylates insulin receptor substrate-1,-3, and-4 but not-2: isoform specific determinants of specificity in insulin signaling. Endocrinology 2008; 149:2451-2458.
40. Jacob AI, Horovitz-Fried M, Aga-Mizrachi S, et al. The regulatory domain of protein kinase C delta positively regulates insulin receptor signaling. J Mol Endocrinol 2010; 44:155-169.
41. Raaijmakers JH, Bos JL. Specificity in Ras and Rap signaling. J Biol Chem 2009; 284:10995-10999.
42. Dremier S, Milenkovic M, Blancquaert S, et al. Cyclic adenosine 3',5'-mono-phosphate (cAMP)-dependent protein kinases, but not exchange proteins directly activated by cAMP (Epac), mediate thyrotropin/cAMP-dependent regulation of thyroid cells. Endocrinology 2007; 148:4612-4622.
43. Hong K, Lou L, Gupta S, et al. A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation. J Biol Chem 2008; 283:231 29-23138.
44. Vuchak LA, Tsygankova OM, Prendergast GV, Meinkoth JL. Protein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropin. Mol Pharmacol 2009; 76:1123-1129.
45. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Inter Med 2006; 145:660-664.
46. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6:219-228.
47. Piñar D, Boix E, Meana JA, Herrero J. Sunitinib-induced thyrotoxicosis. J Endocrinol Invest 2009; 32:941-942.
48. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6:569-579.
49. Guigon CJ, Cheng S. Novel nongenomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol 2009; 308:63-69.
50. Lin H, Sun M, Tang H, et al. L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidy-linositol 3-kinase. Am J Physiol Cell Physiol 2009; 296:C980-C991.
51. Mousa SA, Bergh JJ, Dier E, et al. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008; 11:183-190.
52. Davis FB, Mousa SA, O'Connor L, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004; 94:1500-1506.
53. Bugge TH, Flick MJ, Danton MJ, et al. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93:5899-5904.
54. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004; 101:6062-6067.
55. Desruisseau-Gonzalvez S, Delori P, Gruffat D, Chabaud O. Polarized secretion of tissue-plasminogen activator in cultured thyroid cells. In vitro Cell Dev Biol 1993; 29A:161-164.
56. Jørgensen M, Mortensen JZ, Madsen AG, et al. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis. Scand J Haematol 1982; 29:217-223.
57. Booth NA, Bennett B, Wijngaards G, Grieve JH. A new life-long hemorrhagic disorder due to excess plasminogen activator. Blood 1983; 61:267-275.
58. Ulisse S, Baldini E, Toller M, et al. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer 2006; 42:2631-2638.
59. Ito Y, Takeda T, Kobayashi T, et al. Plasminogen activation system in active even in thyroid tumors: an immunohistochemical study. Anticancer Res 1996; 16:81-89.
60. Lansink M, Koolwijk P, van Hinsbergh V, Kooistra T. Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression. Blood 1998; 92:927-938.
61. Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 2009; 101:656-664.
62. Zhang L, Seiffert D, Fowler BJ, et al. Plasminogen has a broad extrahepatic distribution. Thromb Haemost 2002; 87:493-501.
63. Franchini M, Montagnana M, Manzato F, Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009; 35:288-294.
64. Erem C. Coagulation and fibrinolysis in thyroid dysfunction. Endocrine 2009; 36:110-118.
65. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis-a systematic review. J Clin Endocrinol Metab 2007; 92:2415-2420.
66. Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010;95:186-193.
67. Metso S, Auvinen A, Salmi J, et al. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol 2008; 68:450-457.
68. Flynn RW, Macdonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006; 91:2159-2164.
69. Li Y, Chen H, Tan J, et al. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease: indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur J Clin Invest 1998; 28:1050-1054.
70. Bubber P, Bubber N, Bansal DD. Effect of thyroxine on plasminogen activator and inhibitor activity in rat. Indian J Exp Biol 2009; 47:147-150.